Dr. Robert McCormack of Veridex/Johnson & Johnson –
On The New Cancer Blood Test

Dr. Robert McCormack

Dr. Robert McCormack is the Head of Technology Innovation and Strategy, at Veridex, A Johnson & Johnson Company. He has a vast knowledge of Circulating Tumor Cell (CTC) technology and how physicians use it to monitor therapy. The latest news in cancer research is a new test developed by researchers at Massachusetts General Hospital’s cancer center. The test is designed to detect circulating cancer cells with a non-invasive blood test. JNJ’s Veridex Division is joining forces with this research team to bring this test to market. Dr. McCormack joined us to explain the current and future capabilities and applications of this technology. To monitor progress on this promising testing technology and its clinical applications, go to: or

Comments are closed.